Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity

Cancer Immunology Immunotherapy

Volumn 37, Issue 1, 1993, Pages 7-14

  Balemans, L T M ^a,b   Mattijssen, V ^c   Steerenberg, P A ^a   Van Driel, B E M ^a   De Mulder, P H M ^c   Den Otter, W ^a,b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Guinea pig hepatoma; Interleukin 2; Locoregional immunotherapy; Polyethylene glycol

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 2 DERIVATIVE; MACROGOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EOSINOPHIL; FEMALE; GUINEA PIG; INTRATUMORAL DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MALE; NONHUMAN; PRIORITY JOURNAL; REGIONAL PERFUSION; SKIN TUMOR;

ANIMAL; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES, NEURONAL; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; FIBROSIS; GRANULOCYTES; GUINEA PIGS; IMMUNITY, CELLULAR; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRALYMPHATIC; INTERLEUKIN-2; LEUKOCYTE L1 ANTIGEN COMPLEX; LIVER NEOPLASMS, EXPERIMENTAL; LYMPHATIC METASTASIS; MALE; NEOPLASM TRANSPLANTATION; REMISSION INDUCTION; SPLENIC NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 0027176104     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/BF01516936     Document Type: Article

References (44)

1. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice
2. Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically
3. T cell involvement in adoptive transfer of line 10 tumor immunity in strain 2 guinea pigs
4. Selective localization of tumor immune spleen cells at the tumor challenge site after adoptive transfer of line 10 tumor immunity in strain 2 guinea pigs
5. Tumour regression by IL-2 mediated stagnation of blood flow
6. Effective immunotherapy with local low doses of interleukin-2
7. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
8. Interleukin-2 dependent natural killer (NK) cell lines from patients with primary T cell immunodeficiencies
9. Interleukin-2 activated tumor inhibition in vivo depends on the systemic involvement of host immunoreactivity
10. Long term culture of tumor-specific cytotoxic T cells
11. A long term culture of human antigen-specific cytotoxic T cell lines
12. Lymphokine-activated killer cell phenomenon: lysis of natural killer-resistant fresh solid tumor cells by interleukin-2 activated autologous human peripheral blood lymphocytes
13. Lysis of natural killer resistant fresh solid tumor cells by interleukin 2 activated autologous human peripheral blood lymphocytes
14. Histopathology of tumor regression after intralesional injection of Mycobacteriumbovis. IV. Development of immunity to tumor cells and BCG
15. Interleukin 2 augments natural killer cell activity
16. Histophotometric estimation of volume density of collagen as an indication of fibrosis in rat liver
17. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin 2 chemically modified with water-soluble polymers
18. In vivo administration of purified human interleukin-2. II. Half life, immunological effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL-2
19. Effector cells of low-dose IL-2 immunotherapy in tumor-bearing mice: tumor cell killing by CD8+ cytotoxic T-lymphocytes and macrophages
20. Polyethylene glycol modified interleukin-2 superior to interleukin-2 in locoregional immunotherapy of established guinea pig tumors
21. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin 2
22. Tumour regression after intralesional injection of interleukin-2 (IL-2) in bladder cancer
23. Antigenicity of a new diethylnitrosamine induced transplantable guinea pig hepatoma: pathology and formation of ascites variant
24. Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin 2 to patients with metastatic cancer
25. A new approach to the adoptive immunotherapy of cancer with tumor infiltrating lymphocytes
26. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone
27. Adoptive immunotherapy for cancer
28. Local interleukin-2 therapy in bovine ocular squamous cell carcinoma
29. Mechanism of immunological eradication of a syngeneic guinea pig tumor: participation of a component(s) of recipient origin in the expression of systemic adoptive immunity
30. Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells
31. In vivo antitumor activity of tumor infiltrating lymphocytes expanded in recombinant interleukin-2
32. Tumor infiltraing leukocytes (Tils) during progressive tumor growth and BCG-mediated tumor regression
33. Tumor rejection after adoptive transfer of line 10 immunity is mediated by two T-cell subpopulations
34. Mechanisms of BCG induced regression of line 10 hepatocarcinoma in the guinea pig
35. Functional diversity of T lymphocytes due to secretion of different cytokine patterns
36. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease
37. Response of resting peripheral blood natural killer cells to interleukin-2
38. Local interleukin 2 therapy of mouse mammary tumors of various immunogenicities
39. Peri-tumor interleukin-2 causes systemic therapeutic effect via interferon-γ induction
40. Immunologic aspects of fibrosis in mouse mammary carcinomas
41. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
42. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2
43. Suppression of tumor growth at the site of infection with living bacillus Calmette-Guérin
44. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol modified interleukin 2 in murine tumor models